On the TRAIL of obesity and diabetes

Trends in Endocrinology and Metabolism

Volumn 24, Issue 11, 2013, Pages 578-587

  Harith, Hanis H ^a,b   Morris, Margaret J ^a   Kavurma, Mary M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Apoptosis; Diabetes; Non apoptotic signaling; Obesity; TRAIL

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CASPASE 10; CASPASE 3; CASPASE 8; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 3; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPROTEGERIN; PROTEIN BID; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RECEPTOR INTERACTING PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; APOPTOSIS; ATHEROSCLEROSIS; BODY MASS; CANCER CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL INFILTRATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENERGY BALANCE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FAT MASS; FATTY ACID OXIDATION; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID DIET; LIPOGENESIS; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UBIQUITINATION; WEIGHT GAIN; WEIGHT REDUCTION; WILD TYPE;

APOPTOSIS; DIABETES; NON-APOPTOTIC SIGNALING; OBESITY; TRAIL;

ANIMALS; DIABETES MELLITUS; HUMANS; OBESITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84886290597     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2013.07.001     Document Type: Review

References (80)

1. Finucane M.M., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011, 377:557-567.
2. Morris M.J. Cardiovascular and metabolic effects of obesity. Clin. Exp. Pharmacol. Physiol. 2008, 35:416-419.
3. van Kruijsdijk R.C., et al. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2569-2578.
4. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011, 29:415-445.
5. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 2011, 121:2111-2117.
6. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148:852-871.
7. Odegaard J.I., Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013, 339:172-177.
8. Kim J-A., et al. Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 2008, 102:401-414.
9. Wang C-H., et al. Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes. FEBS J. 2013, 280:1039-1050.
10. Holmstrom M.H., et al. Tissue-specific control of mitochondrial respiration in obesity-related insulin resistance and diabetes. Am. J. Physiol. Endocrinol. Metab. 2012, 302:E731-E739.
11. Wiley S.R., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
12. Azahri N.S., Kavurma M.M. Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand. Cell. Mol. Life Sci. 2013, (in press). 10.1007/s00018-013-1264-x.
13. Kavurma M.M., Bennett M.R. Expression, regulation and function of trail in atherosclerosis. Biochem. Pharmacol. 2008, 75:1441-1450.
14. Kavurma M.M., et al. Death receptors and their ligands in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1694-1702.
15. Azijli K., et al. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ. 2013, 20:858-868.
16. Gonzalvez F., Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010, 29:4752-4765.
17. Vigneri P., et al. Diabetes and cancer. Endocr. Relat. Cancer 2009, 16:1103-1123.
18. Krieg A., et al. TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential. Br. J. Cancer 2003, 88:918-927.
19. Wang P., et al. Novel transcript variants of TRAIL show different activities in activation of NF-kappaB and apoptosis. Life Sci. 2011, 89:839-846.
20. Mariani S.M., Krammer P.H. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 1998, 28:973-982.
21. Di Pietro R., Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J. Cell. Physiol. 2004, 201:331-340.
22. Emery J.G., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998, 273:14363-14367.
23. Schneider P., et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Biol. Chem. 2003, 278:5444-5454.
24. Secchiero P., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003, 107:2250-2256.
25. Keuper M., et al. TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma. Cell Death Dis. 2013, 4:e474.
26. Bernardi S., et al. TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin. Sci. 2012, 123:547-555.
27. Eeckhoute J., et al. Coordinated regulation of PPARgamma expression and activity through control of chromatin structure in adipogenesis and obesity. PPAR Res. 2012, 2012:164140.
28. -/- mice. Diabetologia 2011, 54:3157-3167.
29. Volpato S., et al. Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 2011, 215:452-458.
30. Australian Institute of Health and Welfare (AIHW) Diabetes: Australian facts 2008 2008, AIHW.
31. Centers for Disease Control, Prevention National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States 2011, US Department of Health and Human Services.
32. Danaei G., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378:31-40.
33. Thomas H.E., et al. Beta cell apoptosis in diabetes. Apoptosis 2009, 14:1389-1404.
34. Soleimanpour S.A., Stoffers D.A. The pancreatic β cell and type 1 diabetes: innocent bystander or active participant?. Trends Endocrinol. Metab. 2013, 24:324-331.
35. Cheung S.S., et al. Tumor necrosis factor-related apoptosis-inducing ligand and CD56 expression in patients with type 1 diabetes mellitus. Pancreas 2005, 30:105-114.
36. Salehi E., et al. Increased expression of TRAIL and its receptors on peripheral T-cells in type 1 diabetic patients. Iran. J. Immunol. 2007, 4:197-205.
37. Sanlioglu A.D., et al. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas 2008, 36:385-393.
38. Ou D., et al. TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction. Diabetologia 2002, 45:1678-1688.
39. Ou D., et al. Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB. Hum. Immunol. 2005, 66:799-809.
40. Thomas F., et al. A tripartite anoikis-like mechanism causes early isolated islet apoptosis. Surgery 2001, 130:333-338.
41. Ou D., et al. Synergistic inhibition of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human pancreatic beta cells by Bcl-2 and X-linked inhibitor of apoptosis. Hum. Immunol. 2005, 66:274-284.
42. -/- mice. Nat. Immunol. 2003, 4:255-260.
43. Lamhamedi-Cherradi S-E., et al. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 2003, 52:2274-2278.
44. Kang S., et al. Systemic delivery of TNF-related apoptosis-inducing ligand (TRAIL) elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobese diabetic mice. Endocrinology 2010, 151:5638-5646.
45. Dirice E., et al. Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats. Hum. Gene Ther. 2009, 20:1177-1189.
46. Zauli G., et al. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes 2010, 59:1261-1265.
47. Rønn S.G., et al. Diabetes and suppressors of cytokine signaling proteins. Diabetes 2007, 56:541-548.
48. Jiang H., et al. TIMP-1 transgenic mice recover from diabetes induced by multiple low-dose streptozotocin. Diabetes 2007, 56:49-56.
49. Ashley D.T., et al. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism 2011, 60:994-1000.
50. O'Sullivan E.P., et al. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. Diabetes Metab. Res. Rev. 2010, 26:496-502.
51. Bisgin A., et al. Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients. Diabetes Res. Clin. Pract. 2012, 96:e84-e86.
52. Chang Y-H., et al. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. Metabolism 2011, 60:1064-1069.
53. Kawano N., et al. Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2011, 91:316-320.
54. Imai Y., et al. Islet inflammation: a unifying target for diabetes treatment?. Trends Endocrinol. Metab. 2013, 24:351-360.
55. Kang S., et al. TRAIL upregulates decoy receptor 1 and mediates resistance to apoptosis in insulin-secreting INS-1 cells. Biochem. Biophys. Res. Commun. 2010, 396:731-735.
56. Blazquez-Medela A.M., et al. Osteoprotegerin and diabetes-associated pathologies. Curr. Mol. Med. 2011, 11:401-416.
57. Choi J.W., et al. Associations of serum TRAIL concentrations, anthropometric variables, and serum lipid parameters in healthy adults. Ann. Clin. Lab. Sci. 2004, 34:400-404.
58. Biolo G., et al. The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans. Clin. Nutr. 2012, 105:12-20.
59. Brombo G., et al. Association of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with central adiposity and low-density lipoprotein cholesterol. PLoS ONE 2013, 8:e58225.
60. Mori K., et al. Association of serum TRAIL level with coronary artery disease. Thromb. Res. 2010, 125:322-325.
61. Davenport C., et al. The effect of exercise on osteoprotegerin and TNF-related apoptosis-inducing ligand in obese patients. Eur. J. Clin. Invest. 2012, 42:1173-1179.
62. Ugur-Altun B., Altun A. Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women. Arch. Med. Res. 2007, 38:891-896.
63. Holecki M., et al. The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. Obesity 2007, 15:1925-1929.
64. Ugur-Altun B., et al. The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. Diabetes Res. Clin. Pract. 2005, 68:217-222.
65. Jorgensen G.M., et al. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. Eur. J. Endocrinol. 2009, 161:95-101.
66. Gannage-Yared M.H., et al. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin. Endocrinol. 2006, 64:652-658.
67. Nabipour I., et al. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism 2010, 59:742-747.
68. Gannage-Yared M.H., et al. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur. J. Endocrinol. 2008, 158:353-359.
69. An J.J., et al. Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med. J. 2007, 48:765-772.
70. Montagnana M., et al. The role of osteoprotegerin in cardiovascular disease. Ann. Med. 2012, 45:254-264.
71. Augoulea A., et al. Osteoprotegerin as a marker of atherosclerosis in diabetic patients. Int. J. Endocrinol. 2013, 2013:6.
72. Reaven G.M. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. J. Clin. Hypertens. (Greenwich) 2011, 13:238-243.
73. Reinhard H., et al. Osteoprotegerin and mortality in Type 2 diabetic patients. Diabetes Care 2010, 33:2561-2566.
74. Schrader J., et al. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia 2007, 50:1243-1247.
75. Toffoli B., et al. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol. Cell. Endocrinol. 2011, 331:136-142.
76. Yaturu S., et al. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. Cytokine 2008, 44:168-171.
77. Altinova A.E., et al. Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. Scand. J. Clin. Lab. Invest. 2011, 71:340-343.
78. Park J.S., et al. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur. J. Endocrinol. 2011, 164:69-74.
79. Marcuzzi A., et al. TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide. Cytokine 2012, 60:43-46.
80. Secchiero P., et al. C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway. Clin. Cancer Res. 2013, 19:1949-1959.